Element Biosciences, developer of a new and disruptive DNA sequencing platform, recently announced that the company has closed its acquisition of Loop Genomics, a long-read solutions company that enables short-read sequencers to obtain long range information. Loop Genomics’ Chief Executive Officer and Founder, Tuval Ben-Yehezkel, PhD, will join Element Biosciences’ leadership team as Senior Director, Applications.
As part of this acquisition, Element Biosciences will offer both short-read and long-read sequencing on a common platform. By combining Element’s highly accurate and cost-effective short-read platform with Loop’s easy and scalable long-read solutions, customers will be able to access both short- and long-read applications on the same platform with unprecedented performance, cost, and flexibility.
“Loop Genomics has successfully commercialized innovative products that bring long-read resolution to short-read platforms in a wide variety of genetic analysis applications. We are thrilled to have the Loop Genomics team join us on our journey to open the world of biology to new possibilities,” said Molly He, PhD, co-founder and chief executive officer of Element Biosciences.
“Element’s new sequencer, now armed with long-read capabilities, is positioned to disrupt the genomics space. We are excited to join forces with the team at Element and are looking forward to providing our customers with superior short- and long-read sequencing products,” said Tuval Ben-Yehezkel.
Element’s inaugural virtual event on March 14, 2022, will provide more details on the Loop Genomics technology and its integration with the Element platform. To register for the event, please visit https://registration.elementbiosciences.com/.
To learn more, click here.
Equiva Health recently presented a webinar titled Beyond Patient Education and PTX: Moving to Health Relationship Management.
The webinar’s themes explore how patient education approaches have dovetailed with initiatives to improve patient experience, the intertwining of evolving patient engagement and digital health initiatives, the challenges of moving to digital health, and success stories in adopting new digital approaches to patient engagement. The discussion also includes key concepts in moving beyond “engagement” toward a more robust Health Relationship Management model designed to mobilize individuals toward intelligent actions.
The recorded version of this webinar is now available here.
A group of CoverMyMeds veterans led by co-founder and CEO Matt Scantland are onto their next startup with a focus on migraines and autoimmune diseases such as rheumatoid arthritis, psoriasis, ulcerative colitis, and Crohn’s disease. The app-based program is provided through employers.
AndHealth has closed more than $57 million in financing led by Francisco Partners, with participation from the American Medical Association’s venture capital arm Health 2047, Kirkland & Ellis and Twofold Ventures.
McKesson acquired CoverMyMeds for $1.4 billion in 2017.
To read more, click here.
SWORD Health, a virtual musculoskeletal care provider, has appointed a Chief Medical Officer. Dr. Vijay Yanamadala will lead the clinical affairs team.
He has an extensive background in the treatment of patients with spinal deformities and comorbidities. Yanamadala currently serves as the Systemwide Medical Director of Spine Quality and Surgical Optimization at Hartford Healthcare in Connecticut.
To read more, click here.
The Dallas-based accelerator Health Wildcatters has a new home: biotech business park Pagasus Park.
The 23 acre campus formerly was home to Mobil Oil Corp. until J. Small Investments and Lyda Hill Philanthropies collaborated on transforming it into a science and tech hub.
Other businesses at the site include Blackstone Launchpad powered by Techstars, Health TechFWs Thinklab, Taysha Gene Therapies, and UT Southwestern’s Office for Technology Development.
To read more, click here.
Picture: akindo, Getty Images
